Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2017
SIETES contiene 92005 citas

 
 
 1 a 20 de 431 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Jhang KM, Huang J-Y, Nfor ON, Tung Y-C, Ku W-Y, Lee C-T, Liaw Y-P. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol 2017;73:911-6. [Ref.ID 101996]
2. Cita con resumen
Lin H-L, Lin H-C, Tseng Y-F, Chen SC, Hsu C-Y. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol 2017;73:365-71. [Ref.ID 101941]
3. Cita con resumen
Anónimo. Safinamide et maladie de Parkinson avec fluctuations motrices. Prescrire 2017;37:90-1. [Ref.ID 101438]
4. Cita con resumen
Chen HK, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, Hystad P, Martin RV, Murray BJ, Jessiman B, Wilton AS, Kopp A, Burnett RT. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet 2017;389:718-26. [Ref.ID 101409]
6. Cita con resumen
Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]
7.Enlace a cita original
Renoux C, Dell'Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P, the Canadian Network for Observational Drug Effect Studies (CNODES) investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol 2016;82:461-72. [Ref.ID 100688]
8. Cita con resumen
Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96-8. [Ref.ID 100620]
9. Cita con resumen
Anónimo. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther 2016;58:74-5. [Ref.ID 100456]
10.Enlace a cita original Cita con resumen
Anónimo. FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. FDA U.S. Food and Drug Administration 2016:29 de abril. [Ref.ID 100215]
11. Cita con resumen
Casassus B. France releases interim report on drug trial disaster. Lancet 2016;387:634-5. [Ref.ID 100049]
13.Enlace a cita original Cita con resumen
Crispo JAG, Fortin Y, Thibault DP, Emons M, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison DR, Willis AW, Krewski D. Trends in inpatient antiparkinson drug use in the USA, 2001-2012. Eur J Clin Pharmacol 2015;71:1011-9. [Ref.ID 99381]
14. Cita con resumen
Anónimo. Droxidopa (Northera) for neurogenic orthostatic hypotension. Med Lett Drugs Ther 2015;57:92-3. [Ref.ID 99270]
15.Enlace a cita original Cita con resumen
Lang Y, Gong D, Fan Y. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. Pharmacoepidemiol Drug Saf 2015;24:559-66. [Ref.ID 99175]
17.
Prasad V. Statins, primary prevention, and overall mortality. Ann Intern Med 2014;160:867-9. [Ref.ID 97767]
18. Cita con resumen
Anónimo. Rotigotine transdermique dans les jambes sans repos: troubles compulsifs. Prescrire 2014;34:351. [Ref.ID 97561]
19. Cita con resumen
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670-83. [Ref.ID 97495]
Seleccionar todas
 
 1 a 20 de 431 siguiente >>